Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer
(NSCLC) often develop resistance to current standard third-generation EGFR tyrosine …

Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have
demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however …

9006 Background: Initial results with the amivantamab (ami) and lazertinib (laz) regimen
showed encouraging efficacy in patients (pts) whose disease progressed after standard-of …

9006 Background: Preliminary efficacy was observed with the combination of amivantamab,
an EGFR-MET bispecific antibody, and lazertinib, a 3rd-generation tyrosine kinase inhibitor …

Background Amivantamab plus carboplatin–pemetrexed (chemotherapy) with and without
lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor …

Background Osimertinib became the standard treatment for patients with untreated EGFR-
mutant advanced non-small cell lung cancer (aNSCLC) following results reported in the …

Background Amivantamab (ami), an EGFR-MET bispecific antibody with immune cell-
directing activity, plus lazertinib (laz), a CNS-penetrant, 3 rd-generation EGFR TKI, have …

Importance Although treatment with first-generation epidermal growth factor receptor (EGFR)–
tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …

Purpose: We report the final analysis of JVDL (NCT02789345), which examined the
combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2 …

Aim: Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor. We
report real-world effectiveness and safety data. Patients & methods: EGFR T790M positive …